V Simon Abraham

Stop pretending this is about cracking down on fraud when Trump literally let people who stole hundreds of millions in Medicare and Medicaid money walk free. One guy stole $1.3 billion and served 14 months of a 20-year sentence. When a reporter asked the DOJ about it, they refused to answer. That’s the hypocrisy people are angry about. Republicans want to talk tough on fraud while protecting the biggest fraudsters when they’re politically connected. If fraud is wrong, then it should be wrong for everyone.

"Would you marry someone less intelligent than you?" Outright "no": Women: 45% Men: 8% Women are nearly 6x more likely to rule it out entirely. The single largest gender disparity in our deep-question dataset.

The FDA Commissioner role is open. This is a pivotal moment for American medicine — & for American patients. Here’s what I believe the next Commissioner should stand for. Not as a wish list. As a baseline. 🔬 1. BRING BACK THE ADCOMS — AND MAKE THEM COUNT. Advisory Committee meetings are one of the FDA’s most powerful tools for transparency. They should return in full force. Open. Public. And real. Patients, doctors, scientists, advocates, & skeptics should all be able to speak. But if you want to speak, you fill out a financial conflict-of-interest form under penalty of perjury — & you read it out loud at the podium before you say another word. Every single person. And if the issues are complex and the science requires more than one day, then take the time. Don’t cut people off because the schedule says so. The public deserves to see exactly how these decisions are made. Real transparency builds real trust. ⚖️ 2. STOP ASKING ONLY “IS IT SAFE ENOUGH TO APPROVE?” — START ASKING “WHAT HAPPENS IF WE DON’T?” For rare diseases. For serious conditions with no good options. For patients who don’t have ten years to wait for traditional trials that may never be feasible. Every regulatory decision carries two risks: the risk of approving something, and the risk of not approving it. Both are real. Both affect real people. When traditional gold-standard trials aren’t practical, we should still be able to move with urgency — but only when paired with strong post-approval commitments and rigorous safety monitoring. We can give desperate patients a chance without abandoning scientific integrity. 🇺🇸 3. THE FDA’S ONLY CLIENT IS THE AMERICAN PATIENT. FULL STOP. The FDA exists to serve patients — not outside interests or external pressures of any kind. It must continue protecting the public from products that carry real, known risks but offer no meaningful clinical benefit. At the same time, when there is credible evidence that a treatment can help patients with serious conditions, Americans and their physicians should be trusted to make informed decisions once they have complete and honest information about the risks, benefits, and alternatives. The FDA’s job is to make sure the science is sound and the information is clear. Then let patients and doctors do what’s best for them. These principles matter because the FDA’s decisions affect every family in this country. Note: This is a simple social media post and not a massive policy document. The issues are FAR more nuanced, there are challenges and risks with each of the things I said above, and I recognize that. But it's intended to serve as a discussion starter. We must always strive to improve, and we can when we have open debate and dialogue.